New Study Tracking Type 1 Diabetes Risk in Adults: What You Need to Know

When we think of Type 1 diabetes, we often picture children receiving a diagnosis. But the reality is different: more than half of all Type 1 diabetes cases are actually diagnosed in adults. Despite this, most research on predicting Type 1 diabetes has focused on children, leaving a significant gap in what we know about how the disease develops in grown-ups.

Understanding the natural history of Type 1 diabetes in adults—how it progresses from its earliest signs to diagnosis—is crucial for improving prediction and potentially intervening before symptoms appear.

The Type 1 Diabetes Risk in Adults (T1DRA) study launched in November 2023 and will run through May 2027. It is recruiting 20,000 participants from two groups: people from the general UK population and adults who have relatives with Type 1 diabetes (since having a family member with the condition increases risk).

The process is designed to be simple and accessible. Participants consent online and receive a capillary blood collection kit by mail, which they can use to take a small blood sample at home. They then mail the sample back to the laboratory for testing.

This remote-sampling approach removes barriers to participation and allows researchers to study a large, diverse group of adults.

Type 1 diabetes can be predicted by detecting multiple circulating islet autoantibodies—proteins in the blood that indicate the immune system is attacking the insulin-producing cells in the pancreas. The T1DRA study screens for several of these autoantibodies: those against truncated glutamate decarboxylase 65 (tGAD65), insulinoma-associated antigen-2 (IA-2), zinc transporter 8 (ZnT8), and insulin.

The laboratory uses a two-step testing process. First, samples are screened using a multiplex lumiescence assay to identify which ones contain autoantibodies. Samples that test positive in this initial screening are then retested with more detailed individual assays to confirm the findings.

If a participant's blood shows one or more islet autoantibodies, they are recontacted by the research team. A confirmation sample is requested to verify the initial result.

Once autoantibody positivity is confirmed, participants receive education about the symptoms of Type 1 diabetes—important knowledge in case the disease develops. They are then invited to take part in annual monitoring visits, which will help researchers accurately measure the risk that Type 1 diabetes will develop in the future.

The confirmation sample is also analyzed in more detail to measure autoantibody characteristics, such as how strongly they bind to their targets. This deeper analysis may provide additional insights into the disease progression process.

By following a large group of adults over time, the T1DRA study will build a clearer picture of how Type 1 diabetes develops in the population where it is most commonly diagnosed. This knowledge is foundational for developing better prediction models and understanding the factors that influence whether someone with autoantibodies will go on to develop the disease.

The study represents an important step toward personalized approaches to Type 1 diabetes prevention and early intervention in adults.

Source: BMJ open. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.